1-3 of 3
Darren A.E. Cross
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Jacqueline H. Starrett, Alexis A. Guernet, Maria Emanuela Cuomo, Kamrine E. Poels, Iris K. van Alderwerelt van Rosenburgh, Amy Nagelberg, Dylan Farnsworth, Kristin S. Price, Hina Khan, Kumar Dilip Ashtekar, Mmaserame Gaefele, Deborah Ayeni, Tyler F. Stewart, Alexandra Kuhlmann, Susan M. Kaech, Arun M. Unni, Robert Homer, William W. Lockwood, Franziska Michor, Sarah B. Goldberg, Mark A. Lemmon, Paul D. Smith, Darren A.E. Cross, Katerina Politi
Journal: Cancer Research
Cancer Res (2020) 80 (10): 2017–2030.
https://doi.org/10.1158/0008-5472.CAN-19-3819
Published: 15 May 2020
View article titled, Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance <em>EGFR</em> Mutations
Open the PDF for Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance <em>EGFR</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors

Ludovic Ménard, Nicolas Floc'h, Matthew J. Martin, Darren A.E. Cross
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (12): 3267–3279.
https://doi.org/10.1158/0008-5472.CAN-17-2195
Published: 14 June 2018
View article titled, Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors
Open the PDF for Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Catherine A. Eberlein, Daniel Stetson, Aleksandra A. Markovets, Katherine J. Al-Kadhimi, Zhongwu Lai, Paul R. Fisher, Catherine B. Meador, Paula Spitzler, Eiki Ichihara, Sarah J. Ross, Miika J. Ahdesmaki, Ambar Ahmed, Laura E. Ratcliffe, Elizabeth L. Christey O'Brien, Claire H. Barnes, Henry Brown, Paul D. Smith, Jonathan R. Dry, Garry Beran, Kenneth S. Thress, Brian Dougherty, William Pao, Darren A.E. Cross
Journal: Cancer Research
Series: Author Choice
Cancer Res (2015) 75 (12): 2489–2500.
https://doi.org/10.1158/0008-5472.CAN-14-3167
Published: 14 June 2015
View article titled, Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Open the PDF for Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models in another window
Includes: Supplementary data